Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Zai Lab Raises $150 Million in US Secondary Offering

publication date: Sep 6, 2018

Zai Lab completed a $150 million secondary offering of NASDAQ-listed shares, selling 7.5 million ADS at $20 each. All together, Zai is developing eight drug projects, six of them in clinical trials. The company is reported to have a $300 million Hong Kong IPO in the works, and on Tuesday, Quan Capital, which shares its top management with Zai, though the two companies are organizationally separate, filed to raise $300 million for its second healthcare VC fund. Zai's stock has dropped 23% since the secondary was first announced last week. More details....

Stock Symbols: (NSDQ: ZLAB)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.